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Abstract
Background: Recurrent bleeding from an intracranial aneurysm after subarachnoid hemorrhage (SAH) is associated
with unfavorable outcome. Recurrent bleeding before aneurysm occlusion can be performed occurs in up to one in
five patients and most often happens within the first 6 h after the primary hemorrhage. Reducing the rate of
recurrent bleeding could be a major factor in improving clinical outcome after SAH. Tranexamic acid (TXA) reduces
the risk of recurrent bleeding but has thus far not been shown to improve functional outcome, probably because
of a higher risk of delayed cerebral ischemia (DCI). To reduce the risk of ultraearly recurrent bleeding, TXA should
be administered as soon as possible after diagnosis and before transportation to a tertiary care center. If TXA is
administered for a short duration (i.e., < 24 h), it may not increase the risk of DCI. The aim of this paper is to present
in detail the statistical analysis plan (SAP) of the ULTRA trial (ULtra-early TRranexamic Acid after Subarachnoid
Hemorrhage), which is currently enrolling patients and investigating whether ultraearly and short-term TXA
treatment in patients with aneurysmal SAH improves clinical outcome at 6 months.
Methods/design: The ULTRA trial is a multicenter, prospective, randomized, open, blinded endpoint, parallel-group
trial currently ongoing at 8 tertiary care centers and 16 of their referral centers in the Netherlands. Participants are
randomized to standard care or to receive TXA at a loading dose of 1 g, immediately followed by 1 g every 8 h for
a maximum of 24 h, in addition to standard care, as soon as SAH is diagnosed. In the TXA group, TXA
administration is stopped immediately prior to treatment (coil or clip) of the causative aneurysm. Primary outcome
is the modified Rankin Scale (mRS) score at 6 months after SAH, dichotomized into good (mRS 0–3) and poor (mRS
4–6) outcomes, assessed blind to treatment allocation. Secondary outcomes include case fatalities at 30 days and at
6 months and causes of poor clinical outcome. Safety outcomes are recurrent bleeding, DCI, hydrocephalus, per-
procedural complications, and other complications such as infections occurring during hospitalization. Data analyses
will be according to this prespecified SAP.
Trial registration: Netherlands Trial Register, NTR3272. Registered on 25 January 2012.
ClinicalTrials.gov, NCT02684812. Registered on 17 February 2016.
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Background
Subarachnoid hemorrhage (SAH) accounts for 5% of all
strokes and has an incidence of 7.9 per 100,000 person-
years [1]. Only 25% of all patients with aneurysmal SAH
have a favorable outcome, and even then, most of these pa-
tients still have severe cognitive dysfunction and functional
disabilities [2]. The case fatality rate in SAH is approxi-
mately 35% due to the initial hemorrhage or subsequent
complications. A frequent complication and one of the
major causes of death and disability is recurrent bleeding
from the aneurysm, which occurs in 4–12% of patients who
reach the hospital within the first 24 h [3–9]. The percent-
age of recurrent bleeding increases to 17% if cases of recur-
rent bleeding presenting within the first 6 h after the
primary hemorrhage (“ultraearly recurrent bleeding”) are
also counted [7, 10]. In daily clinical practice, aneurysm
treatment is often postponed by either a delay in diagnosis
or transfer to a tertiary treatment center [11–13]. Therefore,
despite several efforts to improve the logistic processes, ultra-
early recurrent bleeding still occurs before the aneurysm is
secured. A strategy in addition to early aneurysm occlusion
to reduce the number of recurrent bleedings is treatment
with antifibrinolytic agents prior to aneurysm occlusion. Re-
sults from previous nonrandomized studies using early and
short-term administration of antifibrinolytics showed reduc-
tion of recurrent bleeding without an increase in delayed
cerebral ischemia (DCI) [3, 6, 14, 15]. The only randomized
controlled trial of early (< 48 h) and short-term (< 72 h) tran-
examic acid (TXA) treatment confirmed a reduction in re-
current bleeding but did not assess the occurrence of DCI
and was underpowered to show an effect on clinical out-
come [3]. We therefore decided to perform a sufficiently
powered randomized clinical trial in which TXA is adminis-
trated ultraearly (as soon as possible and at least within the
first 24 h after the primary hemorrhage) and for an ultrashort
time period (< 24 h) to reduce the risk of the occurrence of
DCI. The ULTRA (ULtra-early TRanexamic Acid after sub-
arachnoid hemorrhage) trial is a multicenter, phase III, ran-
domized, controlled, open-label, blinded endpoint trial
performed in 8 tertiary care centers and 16 of their referral
centers in the Netherlands (see Appendix for list of partici-
pants). We published the ULTRA trial protocol previously
[16] and now describe the statistical analysis plan (SAP).
Objectives
The primary aim of the ULTRA trial is to evaluate whether
ultraearly and short-term TXA treatment improves clinical
outcome after 6 months in patients with SAH.
Methods/design
Trial protocol development and conduct
The ULTRA trial is registered with the Netherlands Trial
Register (NTR3272; date of registration 25 January 2012)
and ClinicalTrials.gov (2012-000343-26; registered on 17
February 2016). The ethics committee of the Amsterdam
University Medical Centre (Amsterdam UMC, Amsterdam,
the Netherlands) approved the trial protocol on 6 Septem-
ber 2012, starting with two treatment centers and one re-
ferral center. Six treatment centers and sixteen referral
centers joined the study at a later date. The local accredited
ethics committee of each participating hospital approved
the local feasibility of the study protocol. During the course
of the study, the accredited ethics committee approved
three amendments with respect to changes in the inclusion
and exclusion criteria. The study was conducted according
to the principles of the Declaration of Helsinki, Dutch le-
gislation regarding medical research involving human sub-
jects [17–20], and good clinical practice (GCP) guidelines
[21]. Because the majority of patients will not be able to
give informed consent at admission, the informed consent
procedure for this study is delayed in a so-called emer-
gency procedure as described previously [16]. All study
sites were monitored by an independent clinical research
associate of the Amsterdam UMC Clinical Research Unit
(Amsterdam, the Netherlands). An independent data and
safety monitoring board (DSMB) monitored the study’s
progress, with a special focus on safety (see below). The
trial will be reported according to the Consolidated Stan-
dards of reporting Trials (CONSORT) guidelines [22].
Inclusion and exclusion criteria are described in the previ-
ously published study protocol [16]. Adult patients with SAH,
diagnosed by noncontrast computed tomography (CT) within
24 h after the last hemorrhage, were included. During the
trial, “no proficiency of the Dutch or English language” and
“treatment for pulmonary embolism” were added to the ex-
clusion criteria, whereas severe liver failure was removed from
the exclusion criteria after consultation with the vascular in-
ternists. All changes were submitted to the accredited ethics
committee as protocol amendments and were approved.
Randomization and data collection
Patients are randomly allocated in a 1:1 ratio to receive ei-
ther ultraearly TXA treatment or standard care, stratified
by treatment center. TXA is administered as a loading
dose of 1 g, immediately followed by 1 g every 8 h for a
maximum of 24 h, in addition to standard care, as soon as
the SAH is diagnosed. In the TXA group, TXA
administration is stopped immediately prior to treatment
(coil or clip) of the causative aneurysm. To ensure alloca-
tion concealment, the randomization sequence was gener-
ated by using GCP-compliant ALEA® randomization
software (ALEA Clinical, Abcoude, The Netherlands).
Randomization was controlled in each treatment center
and web-based, using a dedicated, password-protected,
SSL-encrypted website. Data management was imple-
mented according to GCP guidelines. Patients’ data until
hospital discharge and 6-month follow-up data are
entered via an electronic case record form in a central
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GCP-compliant web-based database to facilitate on-site
data entry (Oracle Clinical®, Redwood Shores, CA, USA;
OpenClinica LCC and collaborators, open source software,
version 3.6, Waltham, MA, USA, www.OpenClinica.com
and Castor Electronic Data Capture, Ciwit BV, Amsterdam,
The Netherlands, 2018, www.castoredc.com). Security is
guaranteed with login names, login codes, and encrypted
data transfer.
Primary outcome
The primary outcome is clinical outcome at 6 months mea-
sured with the modified Rankin Scale (mRS) score by a
standardized and validated telephone interview, performed
by a trained research nurse who was blinded to treatment
allocation [23, 24]. The mRS is dichotomized into good
(mRS 0–3) and poor (mRS 4–6) outcomes [23, 25].
Secondary outcomes
Secondary outcomes include mRS score dichotomized into
good (mRS scores 0–2) and poor (mRS 3–6) outcomes, or-
dinal mRS score at 6 months, case fatality at 30 days and at 6
months, causes of poor outcome (directly related to primary
SAH, related to a complication of the SAH, related to a com-
plication of treatment, or related to another complication).
Safety
Safety outcomes were classified as follows:
1. Complications of SAH (recurrent bleeding,
hydrocephalus, DCI)
2. Complications of treatment (per-procedural
thromboembolic complication, infarct related to
procedure, per-procedural rupture)
3. Other complications (extracranial thrombosis, deep
venous thrombosis, pulmonary embolism),
hemorrhagic complications, severe hyponatremia,
pneumonia, meningitis, urinary tract infection,
epilepsy, delirium, and Terson’s syndrome
4. Suspected unexpected serious adverse reactions
(SUSARs)
5. Other serious adverse events (SAEs)
Investigators recorded all SAEs during first hospital admis-
sion after ictus and reported any adverse event during first hos-
pital admission after ictus that was not related to SAH.
Although there are more secondary endpoints, this SAP will
focus solely on the clinical (mRS scores and case fatalities) and
safety (complications of SAH, complications of treatment, other
complications, SUSARs, and other SAEs) secondary endpoints.
Statistical methods specified in the study protocol
Sample size calculation
As described in the study protocol [16], the primary endpoint
analysis of this study is based on the difference in percentage of
patients with good outcome (mRS score 0 to 3) at 6 months
after SAH between patients with and without TXA treatment.
It is expected that TXA administration will increase the pro-
portion of patients with a good outcome from 69% to 77.1%.
This expected difference between the TXA and standard
care groups was estimated using the results of renowned
SAH studies and our own data (293 consecutive patients
with aneurysmal SAH, added to angiogram-negative patients
with SAH, treated at the AMC between 2008 and 2011). Of
all patients with SAH who reach the hospital, 69% have a
good outcome (unpublished data). In our data, we find a re-
current bleeding rate of 17%, which is consistent with num-
bers reported in previous studies (11–22%) [3, 6, 8]. Among
patients with recurrent bleeding, an estimated 20% will have
a good outcome. Consequently, the percentage of patients
with a good outcome without recurrent bleeding is 79%. In
the TXA group, the reduction in recurrent bleeding is ex-
pected to be 77% [3, 6], which reduces the rate of recurrent
bleeding to 3.9%. Furthermore, TXA is anticipated to im-
prove the percentage of good outcome in patients with re-
current bleeding from 20% to 30% [3]. Therefore, in the
TXA group, 3.9% will have recurrent bleeding, 30% of whom
will have a good outcome. A two-group chi-square test with
a 0.05 two-sided significance level will have 80% power to
detect the difference between a standard care group propor-
tion of 0.69 and a treatment group proportion of 0.771 (odds
ratio, 1.513) when the sample size in each group is 470 (940
patients in total). Taking some withdrawals into account, a
total of 950 patients will be included.
Originally proposed analyses
In the previously published protocol [16], the originally pro-
posed analyses are described, focusing on the intention-to-
treat (ITT) analysis. In the paragraphs below, the final and
further detailed SAP is presented, including as-treated (AT)
and per-protocol (PP) analyses because use of open-label
TXA may modulate possible treatment effects.
Interim analysis and safety reporting
A DSMB was installed for this study to protect patients and
advise the principal investigator on protecting the safety, valid-
ity, and credibility of the trial. Members include a clinically ex-
perienced neurologist/epidemiologist, an intensivist, and a
statistician. The members were not involved in the trial and
had no competing interests. The tasks, responsibilities, and
working procedures of the DSMB were described in a charter.
The DSMB performed ongoing safety surveillance (every 6
months), especially with regard to the occurrence of SAEs in
terms of increased ischemic events and serious extracranial
thrombotic events, such as pulmonary embolism. Every 6
months, the DSMB receives a report prepared by an inde-
pendent statistician that includes data by treatment group on
primary outcome, predefined safety outcomes, other SAEs,
and SUSARs. The DSMB also checks the assumptions for
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sample size calculations without performing statistical ana-
lysis. Additionally, the DSMB performed one interim analysis
of unblinded effectiveness data during the study. This in-
terim analysis was performed after inclusion of 475 patients
in the trial to assess the strength of the efficacy data when
half of the patients are enrolled.
The DSMB can recommend the steering committee of
the ULTRA trial to:
 Adjust conduct, design, or sample size.
 Terminate the study prematurely when there is clear
and substantial evidence of benefit
The justifications for a recommendation to terminate
the study due to clear benefit will be based on
prespecified stopping boundaries for the primary
endpoint of the study (mRS score at 6 months). As a
stopping rule, the Haybittle-Peto method [26, 27] will
be used: interim efficacy analyses (n = 475): P = 0.001;
final efficacy analyses (n = 950): P = 0.05.
 Terminate the study prematurely when there is
evidence of severe harm
The justifications for a recommendation to
terminate the study due to clear harm will be
based on data showing a notably increase of
(serious) adverse events (including case fatalities)
in the intervention group. No prespecified formal
statistical stopping rule for safety is formulated.
 Terminate the study prematurely in case accrual
rates are too low to provide adequate statistical
power for identifying the primary endpoint.
If one or more of these situations occurs, the clinical
relevance of the results will be incorporated into the de-
cision whether to end the trial prematurely.
Statistical analysis plan
Overall principles
The database will not be unlocked until data regarding ef-
ficacy and safety from all patients have been included in
the database after data verification and validation are
performed and after the SAP has been submitted for publi-
cation. The data analysis will start after the 6-month
follow-up data of the last included patient have been ob-
tained. Analysis of the primary outcome will be performed
according the ITT principle. Given the possible bias of
open-label TXA treatment, primary outcome analysis will
also be done in an AT population and a PP population to
check the robustness of the main analysis, regardless of
the presence of statistical significance in the overall ana-
lysis. Secondary outcomes will be analyzed in the ITT
population, except for the main secondary outcome, mor-
tality at 30 days and at 6 months, which will be analyzed in
the ITT, AT, and PP populations. Safety outcomes will be
analyzed in the ITT and AT populations. Statistical ana-
lyses will be done by the investigators of the ULTRA trial
group (see Acknowledgements section). Statistical uncer-
tainty will be expressed in a two-sided 95% confidence
interval (CI). Statistical analyses are performed using the
IBM SPSS Statistics version 25 software (IBM Corporation,
Armonk, NY, USA).
Fig. 1 Trial allocation profile (Consolidated Standards of Reporting Trials [CONSORT])
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Handling of missing data
In case of missing data, every attempt will be made to re-
trieve the data. Because loss to follow-up is expected to be
very low (< 1% missing data on the primary outcome), out-
come data will not be imputed. We will state which data are
missing and calculate frequencies using the total number of
patients with available data. When a patient is lost to follow-
up missing his/her 6-month mRS score, this patient cannot
be included in the analysis of the primary outcome. If pos-
sible, these patients will be included in the secondary out-
come analyses. When a patient has withdrawn consent, we
will use all available data up until withdrawal of consent [28].
Definition of analysis sets
ITT population All randomized patients will be ana-
lyzed in the treatment group to which they were origin-
ally allocated, regardless of nonadherence or deviations
from protocol (Table 5 in Appendix).
As-treated population Patients will be analyzed in
groups according to treatment received, regardless of allocated
treatment at randomization, thus creating a group that re-
ceived at least one dose of TXA (intervention) and a group
that did not (control). The patients will still be included in the
AT analysis if there was a protocol violation (e.g., TXA admin-
istration not according to study protocol or not meeting inclu-
sion or exclusion criteria).
Per-protocol population In the PP population, patients al-
located to the standard care group who did not receive TXA
will be included, as well as patients allocated to the TXA group
who received TXA (at least one dose). The patients will still be
included in the PP analysis if there was a protocol violation.
Statistical analyses
Patient flow
The flow of participants will be displayed in the CON-
SORT flow diagram (Fig. 1), including the total number
of randomized patients and then showing per treatment
group the numbers receiving allocated treatment, with-
drawing consent, and lost to follow-up.
Protocol deviations
When a patient is randomized but does not adhere to inclu-
sion or exclusion criteria, this is considered a protocol devi-
ation regarding eligibility. When a patient is allocated to the
standard care group but does receive TXA, or when the pa-
tient is allocated to the TXA group but medication adminis-
tration is not according to the protocol, this is considered a
protocol deviation with respect to administration of medica-
tion. Protocol deviations will be line-listed in the Appendix.
Baseline characteristics
The baseline characteristics of all participants in each
treatment group according to allocation will be outlined
in a table without formal statistical testing. The table will
describe the following variables: age, sex, World Feder-
ation of Neurosurgical Societies score, Fisher grade on
noncontrast CT on initial (baseline) scan, medication
use prior to SAH (antiplatelet therapy, anticoagulants,
antihypertensive drugs), location of aneurysm, and treat-
ment modality. Baseline variables will be summarized
using simple descriptive statistics (Table 1). Continuous,
normally distributed variables will be expressed as means
and SDs; continuous, non-normally distributed, and or-
dinal variables will be expressed as medians (25th–75th
percentiles); and categorical variables will be expressed
Table 1 Baseline characteristics of participants prior to
randomization
TXA group
(n = XXX)
Standard care
group
(n = XXX)
Age, yr, mean (SD) NN.N (NN.N) NN.N (NN.N)
Female sex, n (%) NNN (X) NNN (X)
WFNS grade
I, n (%) N (X) N (X)
II, n (%) N (X) N (X)
III, n (%) N (X) N (X)
IV, n (%) N (X) N (X)
V, n (%) N (X) N (X)
Fisher grade
II, n (%) N (X) N (X)
III, n (%) N (X) N (X)
IV, n (%) N (X) N (X)
Medication prior to SAH
Platelet inhibitor, n (%) N (X) N (X)
Anticoagulation, n (%) N (X) N (X)
Antihypertensive, n (%) N (X) N (X)
None, n (%) N (X) N (X)
Location of aneurysm
Anterior circulation, n (%) N (X) N (X)
Posterior circulation, n (%) N (X) N (X)
None, n (%) N (X) N (X)
Treatment modality
Endovascular, n (%) N (X) N (X)
Clipping, n (%) N (X) N (X)
None, n (%) N (X) N (X)
SAH subarachnoid hemorrhage, TXA tranexamic acid, WFNS World Federation
of Neurosurgical Societies
Data presented as mean (range), n (%), or median (IQR), unless
noted otherwise
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as counts and percentages. Normality of data will be ex-
plored by a normal Q-Q plot and tested by the Shapiro-
Wilk test.
Primary outcome
The main statistical analysis will be based on the ITT
principle. The occurrence of the primary outcome, dichoto-
mized mRS score at 6 months (good versus poor as mRS 0 to
3 versus mRS 4 to 6, respectively), will be compared between
the two treatment groups (Table 2). The distribution of the
mRS scores in both treatment groups will be depicted in a
histogram (Fig. 2). Treatment effect will be expressed as a dif-
ference in proportions with corresponding 95% CI and an
odds ratio (OR) estimate with corresponding 95% CI. Add-
itionally, we will analyze the treatment effect on the dichoto-
mized mRS score using multivariable logistic regression,
adjusting for the stratification variable (treatment center) and,
if necessary, clinically relevant baseline imbalances. Effect size
will be expressed as an adjusted OR. The crude and adjusted
analyses will also be performed in both the AT and PP
populations.
Sensitivity analyses
Dichotomized mRS score is chosen as the primary outcome
because results of the analysis are straightforward and easy to
interpret. However, it is also clear that the cutoff is arbitrarily
chosen and information is lost by dichotomization. Ordinal
analysis of outcome data is becoming increasingly more com-
mon in acute stroke trials because it increases statistical
power [29]:
Sensitivity analyses play a crucial role in assessing
the robustness of the findings or conclusions based
on primary analyses of data in clinical trials. They
are a critical way to assess the impact, effect or in-
fluence of key assumptions or variations—such as
different methods of analysis, definitions of out-
comes, protocol deviations, missing data, and out-
liers—on the overall conclusions of a study [30].
Therefore, two sensitivity analyses will be performed:
first, the dichotomized mRS using the cutoff frequently
used in stroke (good outcome, mRS scores 0–2) will be
analyzed using the same analysis as described by the pri-
mary outcome; second, the ordinal mRS score will be ana-
lyzed using an ordinal regression model on the total range
of the mRS under the assumption of proportional odds
(Table 3). If the assumption of ordinal regression does not
hold, we will perform sliding dichotomy analysis [31].
When the loss to follow-up rate is > 10%, a third sensi-
tivity analysis will be performed. Data will be analyzed
according to a worst case scenario; that is, patients lost
to follow-up in the treatment group will have the worst
possible outcome, and patients in the standard care
group will have the best possible outcome.
Secondary outcomes
The secondary outcome analyses will compare case fatality
at 30 days and at 6 months, causes of death or poor out-
come at 6 months, and all safety outcomes between treat-
ment groups (Table 4). The statistical analysis will also be
based on the ITT principle. Treatment effect will be
expressed in a difference in proportions with corresponding
95% CI and an odds ratio (OR) estimate with correspond-
ing 95% CI. The analyses for the main secondary outcome,
mortality at discharge and at 6 months, will also be per-
formed in both the AT and PP populations. The analyses
Fig. 2 Distribution of mRS at 6 months in the intention to treat analysis
Table 2 Primary outcome (modified Rankin Scale score at 6 months) and secondary outcomes
ITT
TXA group Standard care group OR (95% CI) aOR (95% CI)
mRS 0–3 XX XX XX (XX–XX) XX (XX–XX)
Mortality at 30 days XX XX XX (XX–XX) XX (XX–XX)
Mortality at 6 mo XX XX XX (XX–XX) XX (XX–XX)
aOR adjusted odds ratio, CI confidence interval, ITT intention to treat, mRS modified Rankin Scale, OR odds ratio, TXA tranexamic acid
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for the safety outcomes will also be performed in the AT
population.
Trial status
Initially, two treatment centers started recruitment
between July 2013 and February 2014, and six
additional treatment centers started recruitment be-
tween April 2014 and September 2016. A total of 16
referral centers started recruitment between July 2013
and November 2018. All participating centers are in
the Netherlands. Currently, we have enrolled all 955
patients.
Table 4 Safety outcomes during hospital admission
ITT
TXA group (n = xx) Standard care group (n = xx) OR (95% CI)
Any SAE, n (%) NN (X) NN (X) X.XX (X.XX–X.XX)
Recurrent bleeding NN (X) NN (X) X.XX (X.XX–X.XX)
Hydrocephalus NN (X) NN (X) X.XX (X.XX–X.XX)
Delayed cerebral ischemia NN (X) NN (X) X.XX (X.XX–X.XX)
Thromboembolic complications during treatment
Coiling, n (%)
NN (X) NN (X) X.XX (X.XX–X.XX)
Infarct related to procedure
Clipping, n (%)
NN (X) NN (X) X.XX (X.XX–X.XX)
Procedural rupture
Coiling, n (%)
Clipping, n (%)
NN (X) NN (X) X.XX (X.XX–X.XX)
Extracranial thrombosis NN (X) NN (X) X.XX (X.XX–X.XX)
- DVT NN (X) NN (X) X.XX (X.XX–X.XX)
- PE NN (X) NN (X) X.XX (X.XX–X.XX)
Hemorrhagic complication NN (X) NN (X) X.XX (X.XX–X.XX)
Severe hyponatremia NN (X) NN (X) X.XX (X.XX–X.XX)
Pneumonia NN (X) NN (X) X.XX (X.XX–X.XX)
Meningitis NN (X) NN (X) X.XX (X.XX–X.XX)
Urinary tract infection NN (X) NN (X) X.XX (X.XX–X.XX)
Epilepsy NN (X) NN (X) X.XX (X.XX–X.XX)
Delirium NN (X) NN (X) X.XX (X.XX–X.XX)
Terson’s syndrome NN (X) NN (X) X.XX (X.XX–X.XX)
SUSARs NN (X) NN (X) X.XX (X.XX–X.XX)
Other NN (X) NN (X) X.XX (X.XX–X.XX)
CI confidence interval, DVT deep venous thrombosis, ITT intention to treat, OR odds ratio, PE pulmonary embolism, SAE serious adverse event, SUSARs suspected
unexpected serious adverse reactions, TXA tranexamic acid
Table 3 Sensitivity analysis
ITT
TXA group Standard care group OR (95% CI) aOR (95% CI)
Excellent outcome (mRS 0–2) NN (X %) NN (X %) X.XX (X.XX–X.XX) X.XX (X.XX–X.XX)
Ordinal shift mRS) NN (X %) NN (X %) X.XX (X.XX–X.XX) X.XX (X.XX–X.XX)
mRS0
mRS1
mRS2
mRS3
mRS4
mRS5
mRS6
Data are n (%), mean (SD), or median (IQR)
aOR adjusted odds ratio, CI confidence interval, ITT intention to treat, mRS modified Rankin Scale, OR odds ratio, TXA tranexamic acid
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Table 5 Definition of population analysis sets
Analysis population TXA group Standard care group
Intention to treat (“as randomized”) Patients randomized to TXA group:
• Including all protocol deviations
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As treated (“actual treatment”) Patients who received TXA (at least
one dose), regardless of allocated
treatment at randomization:
• Including patients who received
TXA as described according to protocol
• Including patients who received TXA
not following protocol (protocol deviation)
• Including patients with other protocol
deviations
Patients who did not receive TXA, regardless
of allocated treatment at randomization:
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care not following protocol (protocol
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• Including patients with other protocol
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• Including patients with other protocol deviations
TXA tranexamic acid
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